Pfizer manufactured Cabaser is the trade name form of the drug Cabergoline, a potent dopamine agonist which shares some similarities with the drug Bromocriptine insofar as it also inhibits prolactin release, but with a better side effects profile.
Aside from its use in managing prolactin related conditions, Cabaser is also sometimes used to manage Parkinson's Disease, fibroids and as part of a combined approach to treating acromegaly.
Off-Label Use- Similarly to Bromocriptine, Cabaser has been noted to have profound prosexual effects both increasing libido and reducing refraction period significantly which has led to its use as an aphrodisiac. In addition, similarly to Bromocriptine, it has been suggested that use of Cabaser could improve body composition in those engaged in a fitness program.
Due to Cabaser's greater potency in activating D2 receptors it is usually preferred to Bromocriptine now and its lower incidence of side effects makes it much more likely for patients to comply with the dosing regimen compared to Bromocriptine.
Cabaser is typically used for managing prolactin related disorders but its mechanism of action has seen it used in a number of different areas, both for managing diseases and for its purported recreational benefits with respect to libido, and losing bodyfat.
Cabaser, regardless of the purpose of its use, is typically dosed once daily and with most protocols recommending a slow titrating of the drug to minimise side effects such as nausea which are seen in some users. Always read the patient leaflet.